Nutra Pharma Corp (NPHC) Profit After Tax (2010 - 2026)

Nutra Pharma has disclosed Profit After Tax across 17 years of filings, most recently posting -$3.9 million for Q2 2026.

• In Q2 2026, Profit After Tax fell 947.38% year-over-year to -$3.9 million; the TTM figure through Jun 2026 stood at -$5.4 million (down 278.92% YoY), while the FY2025 annual figure was -$2.0 million, down 59.25% from the prior year.
• Profit After Tax came in at -$3.9 million for Q2 2026 at Nutra Pharma, down from -$459675.0 in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $5.0 million in Q1 2022 to a low of -$3.9 million in Q2 2026.
• Average Profit After Tax over 5 years is -$47864.7, with a median of -$323192.5 recorded in 2023.
• Year-over-year, Profit After Tax jumped 226.93% in 2025 and plunged 947.38% in 2026.
• Over 5 years, Profit After Tax stood at $3.2 million in 2022, then slumped by 107.52% to -$243064.0 in 2023, then grew by 5.0% to -$230907.0 in 2024, then tumbled by 111.57% to -$488526.0 in 2025, then slumped by 708.3% to -$3.9 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$3.9 million in Q2 2026, -$459675.0 in Q1 2026, and -$488526.0 in Q4 2025.